The potential application of complement inhibitors-loaded nanosystem for autoimmune diseases via regulation immune balance
The complement is an important arm of the innate immune system, once activated, the complement system rapidly generates large quantities of protein fragments that are potent mediators of inflammation. Recent studies have shown that over-activated complement is the main proinflammatory system of autoimmune diseases (ADs). In addition, activated complements interact with autoantibodies, immune cells exacerbate inflammation, further worsening ADs. With the increasing threat of ADs to human health, complement-based immunotherapy has attracted wide attention. Nevertheless, efficient and targeted delivery of complement inhibitors remains a significant challenge owing to their inherent poor targeting, degradability, and low bioavailability. Nanosystems offer innovative solutions to surmount these obstacles and amplify the potency of complement inhibitors. This prime aim to present the current knowledge of complement in ADs, analyse the function of complement in the pathogenesis and treatment of ADs, we underscore the current situation of nanosystems assisting complement inhibitors in the treatment of ADs. Considering technological, physiological, and clinical validation challenges, we critically appraise the challenges for successfully translating the findings of preclinical studies of these nanosystem assisted-complement inhibitors into the clinic, and future perspectives were also summarised. (The graphical abstract is by BioRender.).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of drug targeting - (2024) vom: 21. März, Seite 1-14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wei, Yaya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmune diseases |
|---|
| Anmerkungen: |
Date Revised 21.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/1061186X.2024.2332730 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369816706 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369816706 | ||
| 003 | DE-627 | ||
| 005 | 20240322000611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240317s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1061186X.2024.2332730 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369816706 | ||
| 035 | |a (NLM)38491993 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wei, Yaya |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The potential application of complement inhibitors-loaded nanosystem for autoimmune diseases via regulation immune balance |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a The complement is an important arm of the innate immune system, once activated, the complement system rapidly generates large quantities of protein fragments that are potent mediators of inflammation. Recent studies have shown that over-activated complement is the main proinflammatory system of autoimmune diseases (ADs). In addition, activated complements interact with autoantibodies, immune cells exacerbate inflammation, further worsening ADs. With the increasing threat of ADs to human health, complement-based immunotherapy has attracted wide attention. Nevertheless, efficient and targeted delivery of complement inhibitors remains a significant challenge owing to their inherent poor targeting, degradability, and low bioavailability. Nanosystems offer innovative solutions to surmount these obstacles and amplify the potency of complement inhibitors. This prime aim to present the current knowledge of complement in ADs, analyse the function of complement in the pathogenesis and treatment of ADs, we underscore the current situation of nanosystems assisting complement inhibitors in the treatment of ADs. Considering technological, physiological, and clinical validation challenges, we critically appraise the challenges for successfully translating the findings of preclinical studies of these nanosystem assisted-complement inhibitors into the clinic, and future perspectives were also summarised. (The graphical abstract is by BioRender.) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Autoimmune diseases | |
| 650 | 4 | |a complement inhibitors | |
| 650 | 4 | |a complement system | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a nanosystem | |
| 700 | 1 | |a Guo, Jueshuo |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Mai, Yaping |e verfasserin |4 aut | |
| 700 | 1 | |a Zuo, Wenbao |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jianhong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g (2024) vom: 21. März, Seite 1-14 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:03 |g pages:1-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1061186X.2024.2332730 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 03 |h 1-14 | ||